jay l. rubenstone, d.o., f.a.c.c valvular heart disease fall 2012
TRANSCRIPT
JAY L. RUBENSTONE, D.O., F.A.C.C
VALVULAR HEART DISEASE
Fall 2012
NORMAL STRUCTUREMITRAL VALVE
• Cross sectional Area 4-6cm2• Anterior and Posterior Leaflets• Chordae Tendineae Papillary Muscles
2
MITRAL STENOSISETIOLOGY & PATHOLOGY
• Rheumatic Fever- 99% • Other• Congenital • Carcinoid• Lupus• Amyloid• Infective Endocarditis• Mucopolysaccharide Disease
3
PATHOPHYSIOLOGY
• Mild MS- orifice <2 cm2• Critical MS- <1 cm2• A-V pressure gradient >20mmHg• Increased LA Pressure• Increase Pulmonary Venous + Capillary
Pressures• Increase Pulmonary Artery Systolic Pressure• Decrease RV Function (when PAS>30-60mmHg)
4
PATHOPHYSIOLOGY
• Pulmonary HTN• Passive Backward Transmission Of Incr. LA pressure
Pulmonary Arteriolar Constriction Organic Obliterative Changes in Pulmonary Vascular Bed RV Failure
5
HISTORY
• Exertional Dyspnea• Cough/Wheezing• Orthopnea/PND/CHF• Hemoptysis-Rupture of Pulm Vein-Brochial Vein
Shunts
6
HISTORY
• Chest Pain-Increase RV Pressures or Unknown Etiology• Systemic Emboli (LA clots)• Increased LA size, Decreased C.O., Atrial Fib, IE• Significantly decreased w/anticoagulation
7
DIAGNOSIS
•Cardiac Catherization•Gorlin Equation
8
NATURAL HISTORY
• Asymptomatic for 15-20yrs following Rheumatic Fever• Additional 5-10 yrs for progression from mild to
severe stenosis• Stenosis progression approx. .09 cm2/yr
9
NATURAL HISTORY
• Presurgical Survival Rates• NYHA Class II 80%-10yrs• Class III 38%-10yrs, 62% 5yrs• Class IV 15%-5yrs
10
MANAGEMENT-MEDICAL
• Endocarditis Prophylaxis• Activity Limitation• Diruetics- Decrease Na Intake• Heart Rate Control for A-fib or Sinus Rhythm• Anticoagulation
11
PERCUTANEOUS BALLOON ANGIOPLASTY
• Moderate-Severe MS• Mild MS- if Pulmonary Artery Pressures or Wedge
Pressure Elevate with Exercise
12
VALVE REPLACEMENT
• Indications• Combined MS/MR• <1.5 cm2-NYHA III or IV• <1 cm2• Class II if Pulm Artery Pressure >70mmHg
• Mortality• 3-8%
• Valve Type-Prosthetic or Bioprosthetic, TAVR
13
MITRAL REGURGITATION
• Etiology• Rheumatic Heart Disease• Infective Endocarditis• Collagen Vascular Disease• Cardiomyopathy• Ischemic Heart Disease
• Mitral Valve Prolapse-most common cause for valve surgery in US
14
PATHOPHYSIOLOGY
• Decreased Impedance to Ventricular Emptying• Determinants of Regurgitant Flow• Instantaneous Size of MV Orifice• Dependent on Preload, Afterload, LV Contractility, LV Size• LA-LV Pressure Gradient dependent on Systemic Vascular
Resistance, LV Pressure, & LV Size
15
PATHOPHYSIOLOGY
• LV Compensation• Increased End Diastolic Volume• Increased Wall Tension• Increased Preload• Increased LV Emptying• Normal Ejection Fraction should be Super Normal >65%
to maintain forward cardiac output and B/P
16
PATHOPHYSIOLOGY
• LV Decompensation• Increase End Systolic Volume• Increased End Diastolic Volume• Leads to Annulus Dilatation (MR begets MR)• Decreased Ejection Fraction and Stroke Volume
17
PATHOPHYSIOLOGY
• Ejection Fraction in Mitral Regurgitation• >65% normal in compensated MR• 50-65% mild impairment• 40-50% moderate-severe impairment• <35% advanced impairmentAs ejection fraction decreases operative risk increases.
18
HISTORY
• Shortness of Breath• Exertional Dyspnea• Congestive Heart Failure• RHF• Significant symptoms in chronic MR usually do
not develop until LV decompensation occurs.
19
HISTORY
• Medical Treatment Survival• 80% 5yr• 60% 10yr• 30-45% 5yr if MR severe
20
MANAGEMENT OF CHRONIC MR
• Medical• Digoxin• Diruetics*• Afterload Reduction• Anticoagulation in A-fib• Endocarditis Prophylaxis
21
MANAGEMENT OF CHRONIC MR
• Surgical• Indications• Asymptomatic Class I
• EF < 60% or LV Systolic Diameter >45mm
• Severe MR Class II, III, or IV • generally considered for surgery unless EF <30%
• Valve Repair vs. Replacement
22
MITRAL VALVE PROLAPSE
• Systolic Click-Murmur Syndrome• Barlow’s Syndrome• Billowing Mitral Valve Syndrome• Floppy Valve Syndrome• Myxomatous Valve Syndrome• Parachute Valve
23
MITRAL VALVE PROLAPSE
• Over diagnosed• 2.4% of population• Females>Males 2:1• Severe MR- Elderly Male>Young Female
24
MVP ETIOLOGY
• Primary Valvular most frequent• Connective Tissue Diseases• Hyperthyroidism• Myotonic Dystrophy• Periarteritis Nodosa• Von Willebrands
25
MVP PATHOLOGY
• Myxomatous Proliferation and Degeneration of Valve Leaflets• Increased Quantity of Acid Mucopolysaccharide in
Middle Layer of Valve Tissue
26
MVP HISTORY
• Most are asymptomatic throughout life• Chest pain, fatigue, anxiety• Orthostasis-questionable autonomic dysfunction• Arrhythmia-SVT, PACs, PVCs• Symptoms of MR if present
27
PHYSICAL EXAMINATION
• Ascultation• Murmur- mid to late crescendo progressing to
holosystolic if MR becomes severe• Click and murmur move closer to S1 during strain phase
of valsalva, sudden standing, and Amyl Nitrate
28
NATURAL HISTORY
• Progressive MR in 15% over 10-15 yrs• Infective Endocarditis• Cerebral Emboli-tearing of endothelial covering of
myxomatous valve with platelet activation• Sudden Cardiac Death-V fib, increased Q-T
interval (not well established)
29
MVP MANAGEMENT
• Endocarditis prophylaxis if MR present• Holter monitor-beta blocker for ectopy?• Aspirin if focal neurological events present• MR-treat like any other MR, valves usually
amenable to repair• *MVP is usually a benign disease*
30
AORTIC VALVENORMAL STRUCTURE
• Valve sits at the base of Aortic Root• Three Leaflets (cusps)-non coronary, right
coronary, left coronary• Cusps give rise to ostea of right coronary artery
and left main coronary artery• Normal cross-sectional area 3-4cm2
31
AORTIC STENOSIS ETIOLOGY AND PATHOLOGY
• Valvular• Supravalvular• Subvalvular• Hyperthrophic Cardiomyopathy
32
CONGENITAL AORTIC STENOSIS
• Unicuspid• Presents less than one year of age
• Bicuspid• Adult Presentation• Chronic turbulent flow• Leads to fibrosis, rigidity, calcification
• Tricuspid• Leaflets of unequal size
33
ACQUIRED AORTIC STENOSIS
• Rheumatic• Rare• Usually mitral valve also involved
• Degenerative or Senile• Most common cause of adult AS• Most common cause of valve replacement• Years of normal mechanical stress leads to
calcium deposits on leaflets• Inflammatory or Infectious component??• >age 65 2% frank AS, 30% Aortic Sclerosis
34
HEMODYNAMICS
• Severe AS• Mean systolic pressure gradient ≥ 40mmHg in
the presence of normal cardiac output• Valve area ≤ 1.0cm2
• Moderate AS• 1-1.5cm2
• Mild AS• 1.5-2cm2
• Aortic Sclerosis
35
HISTORY
• Long latent period of increasing obstruction• Symptoms usually begin in 5th or 6th decade• Angina in 2/3 of patients• Hyperthrophied myocardium• Increased ventricular systolic pressure• All of which increase myocardial oxygen
consumption• Oxygen supply-demand imbalance leads to
subendocardial ischemia
36
HISTORY
• Syncopy• Reduced cerebral perfusion• Vasodilation in the presence of fixed cardiac
output leads to hypotension• Baroreceptor-vasodepression due to high LV
systolic pressure
• Dyspnea (CHF)• Particularly with exertion due to fixed cardiac
output• Pulmonary Venous HTN can lead to CHF
37
NATURAL HISTORY
• Asymptomatic latent period• With moderate-severe AS valve area can
decrease on average 0.12cm2 per year• *Angina, synocopy or CHF• Average 1-3 year survival 50% • Sudden cardiac death rare
38
SURGERY (VALVE REPLACEMENT)
• Indications• Symptomatic Patients -valve area ≤ 1.0cm2
Asymptomatic Patients-progressive LV disfunction (EF <35%) or hypotensive response to mild exercise• Delaying surgery in asymptomatic patients with good
exercise tolerance is controversial• Valve type Prosthetic, Bioprosthetic or TAVR
39
KEEPSURGERY (VALVE REPLACEMENT)
• Results• Effective prosthetic valve area not normal• Surgery replaces Critical AS with Non-critical AS• Symptoms can persist if valve-patient mismatch occurs• 10 year survival –85%
40
AORTIC REGURGITATIONETIOLOGY AND PATHOLOGY
• Valvular• Rheumatic-Fibrotic Retraction of Leaflets• Ankylosing Spondylitis, Behcets, Psoratic Arthritis,
Giant Cell Arteritis• Degenerative AS-75% w/AR• Infective Endocarditis-Leaflet Distruction• Trauma-ascending aortic tear• Bicuspid aortic valve-prolapse or incomplete
closure• Myxomatous Degeneration-like MVP• Appetite suppressant drugs-serotonin related
valve deposits
41
ETIOLOGY AND PATHOLOGY
• Aortic Root Disease-More common than primary valvular. Root Dilatation leads to non-coaptation of leaflets.• Degenerative-Hypertensive Aortic Dilatation• Cystic Medial Necrosis-Classic Marfans Syndrome• Aortic Dissection• Syphilitic Aortitis• Rheumatic Disease-same as valvular
42
HISTORY
• Acute AR• LV cannot accommodate acute regurgitant volume • can lead to cardiovascular collapse
• Chronic AR• Gradual LV enlargement-eccentric hypertrophy• Exertional dyspnea, orthopnea, PND, CHF• Presents 4th or 5th Decade
43
NATURAL HISTORY
• Acute AR• Cardiovascular collapse• Inotrophic agents and vasodilators • Prompt surgical intervention
• Chronic AR• 75% Five Year Survival• 50% Ten Year Survival• Progressive downhill course of CHF, Episodic
Pulmonary Edema, Sudden Cardiac Death
44
MEDICAL TREATMENT
• Acute AR• As above
• Chronic AR• Asymptomatic Mild-Moderate• Follow by Echo Yearly• Endocarditis Prophalaxis for all AR• May not require medical treatment
45
MEDICAL TREATMENT
• Symptomatic Moderate-Severe AR• Limit exertional activity• Aggressively treat B/P• Diuretics• Salt Restriction• Digoxin• Vasodilators (Nifedipine?)
46
SURGICAL TREATMENT
• Indications• Defer surgery for chronic severe AR if good exercise
tolerance, EF greater than 50%, end systolic diameter < 50 mm, and end diastolic diameter < 70 mm
• Be aware that progressive decline in LV function or size increases surgical morbidity and mortality
47
SURGICAL TREATMENT
• Mortality• 3-8% perioperative• 5-10% late mortality with significant preop LV
dysfunction
48